首页|期刊导航|Acta Biochimica et Biophysica Sinica|Immune checkpoint TIM-3 in tumor immunotherapy

Immune checkpoint TIM-3 in tumor immunotherapyOA

中文摘要

Over the past decade,immunotherapy has emerged as a pivotal therapeutic strategy in cancer treatment.Immune checkpoint inhibitors(ICIs),such as CTLA-4 and PD-1 monoclonal antibodies,have demonstrated remarkable clinical efficacy in different types of cancer.However,the overall success rate of immune checkpoint therapies remains low.Investigating alternative immune checkpoint molecules is imperative.T-cell immunoglobulin and mucin-containing molecule-3(TIM-3),which is expressed in T cells,natural killer(NK)cells,macrophages,and dendritic cells,has gained recognition as a promising candidate for tumor immunotherapy.Targeting TIM-3 represents a promising approach for cancer immunotherapy,particularly through the rational design of novel combination therapies with other ICIs.In this review,we present a comprehensive summary of the research advancements concerning the role of TIM-3 in regulating immune responses in different cell types and explore theoretical frameworks for targeting TIM-3 to achieve more effective immunotherapeutic breakthroughs.

Shuaiya Ma;Mengyao Zhu;Chunhong Ma;Chunyang Li

The Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer Hospital,Zhengzhou 450008,ChinaKey Laboratory for Experimental Teratology of Ministry of Education and Department of Immunology,School of Basic Medical Sciences,Cheeloo College of Medicine,Shandong University,Jinan 250012,ChinaKey Laboratory for Experimental Teratology of Ministry of Education and Department of Immunology,School of Basic Medical Sciences,Cheeloo College of Medicine,Shandong University,Jinan 250012,ChinaKey Laboratory for Experimental Teratology of the Ministry of Education and Department of Histology and Embryology,School of Basic Medical Sciences,Cheeloo College of Medicine,Shandong University,Jinan 250012,China

医药卫生

TIM-3immune checkpointimmunotherapy

《Acta Biochimica et Biophysica Sinica》 2026 (1)

P.49-66,18

supported by the grants from the Noncommunicable Chronic Diseases-National Science and Technology Major Project(Nos.2024ZD0519900 and 2024ZD0519902 to C.L.)the National Natural Science Foundation of China(No.82471870 to C.L.,No.82230056 to C.M.,and No.82503129 to S.M.)the Taishan Scholars Program of Shandong Province(No.tsqn202507035 to C.L.)the Henan Province′s Science and Technology Research Project(No.252102311170 to S.M.).

10.3724/abbs.2025235

评论